Hepatitis C Articles (HCV)
Back
	HCV Subgroup Analyses: Cirrhosis/African-Americans/Opoid Replacement/Comorbidities - Abbvie 3D, Ledipasvir/Sofosbuvir       Ledipasir/Sofosbuvir in Compensated Cirrhotics SVR Rates IAC: Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (07/25/14)   Abbvie 3D SVR Rates in Naives Without Cirrhosis(76%) Subgroup Analysis/Across Baseline Characteristics IAC: SAPPHIRE-I Subpopulation Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-naïve Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)   IAC: SAPPHIRE-II Subgroup Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-experienced Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)   EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)   New DAA Phase 3 Studies for genotype 1 at EASL - in both Treatment-naives, treatment-experienced; simultaneous publications   African-Americans/ Opoid Replacement (Methadone) Users SVR Rates, comorbidities - (08/18/14)           View Older Articles   Back to Top   www.natap.org